2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150Cagrilintide is a synthetic long-acting amylin analogue studied for its role in appetite regulation and metabolic coordination.
By enhancing amylin-mediated satiety signaling and slowing gastric emptying, it supports smaller meal size and smoother post-meal nutrient handling. Its complementary pathway has drawn interest alongside GLP-1 agonists for layered appetite and energy-balance signaling.
Cagrilintide is a 37-amino acid, long-acting synthetic analogue of amylin, a peptide hormone that is co-secreted with insulin by pancreatic β-cells and plays a key role in appetite regulation, gastric emptying, and post-meal metabolic signaling [1].
Endogenous amylin acts as a satiety signal, helping coordinate how the body interprets meal size and nutrient intake. Cagrilintide mimics these physiologic actions while exhibiting enhanced molecular stability and prolonged activity compared with endogenous amylin [2].
Cagrilintide’s association with weight regulation is rooted in its ability to amplify amylin-mediated satiety signaling, rather than by directly altering metabolic rate or energy expenditure.
A multicenter, randomized, double-blind phase 2 trial evaluated the dose response, safety, and tolerability of cagrilintide [3]. A total of 706 overweight or obese participants were randomized to once-weekly cagrilintide (0.3–4.5 mg), once-daily liraglutide 3.0 mg, or placebo for 26 weeks, followed by a 6-week off-treatment period.
Results showed that cagrilintide:
Cagrilintide was generally well tolerated, with the most common adverse events including nausea, constipation, and diarrhea, as well as injection-site reactions.
Cagrilintide leads to clinically meaningful, dose-dependent weight reduction with an acceptable safety profile.
Cagrilintide’s relevance to blood-sugar regulation is indirect and comes from its influence on meal timing, gastric emptying, and postprandial signaling.
A randomized phase 2 trial evaluated the efficacy and safety of combined semaglutide and cagrilintide (CagriSema) compared with either agent alone in adults with type 2 diabetes and overweight or obesity [4].
Ninety-two participants were treated for 32 weeks with once-weekly injections of CagriSema, semaglutide, or cagrilintide, escalated to a target dose of 2.4 mg. All participants were on metformin, with or without an SGLT2 inhibitor.
Results showed that CagriSema:
No severe hypoglycaemia or fatal adverse events were observed, indicating that combined amylin and GLP-1 receptor agonism offers additive benefits for weight loss and glycemic control.
Amylin receptors are highly expressed in brain regions involved in integrating sensory input, nutrient status, and fullness cues, particularly within the brainstem and hypothalamus [5].
By engaging these receptors in a sustained manner, cagrilintide reinforces the signals that indicate meal completion and energy sufficiency, affecting both meal size and eating frequency.
This can reduce reward-driven or habitual eating behaviors, especially those that occur independently of physiological hunger.
Because amylin influences gastric emptying and central appetite centers, some individuals on cagrilintide may experience nausea, early fullness, or reduced appetite, especially during initial exposure.
Observed effects are dose- and context-dependent, aligning with its role as a regulatory peptide rather than a forceful metabolic driver.
While GLP-1–based peptides primarily influence insulin and glucose secretion, amylin analogues like cagrilintide contribute distinct satiety and gastric-emptying signals.
Together, these pathways engage multiple, non-redundant nodes to influence appetite perception.
This layered signaling approach allows for enhanced appetite regulation without relying on a single pathway.
Like other peptides that influence gastrointestinal motility and appetite signaling, cagrilintide may not be appropriate in contexts where delayed gastric emptying or altered digestive rhythm could be problematic, like in patients with pre-existing gastroparesis or gastrectomies.
Cagrilintide should also be evaluated in the context of overall metabolic signaling balance, particularly when combined with other appetite-modulating compounds.
References
1 Edwards, B. J. and Morley, J. E. (1992) Amylin. Life Sci., Life Sci 51, 1899–1912
2 Cao, J., Belousoff, M. J., Johnson, R. M., Keov, P., Mariam, Z., Deganutti, G., et al. (2025) Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nat. Commun., Springer Science and Business Media LLC 16, 3389
3 Lau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., et al. (2021) Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet, Elsevier BV 398, 2160–2172
4 Frias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., et al. (2023) Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet, Elsevier BV 402, 720–730
5 Fu, W., Patel, A., Kimura, R., Soudy, R. and Jhamandas, J. H. (2017) Amylin receptor: A potential therapeutic target for Alzheimer’s disease. Trends Mol. Med. 23, 709–720
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Cagrilintide is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Cagrilintide is a long-acting amylin analogue that acts as a calcitonin (CTR)/amylin receptor (AMYR) agonist. In the studies described, cagrilintide is combined with semaglutide, a long-acting GLP-1 receptor agonist, in the fixed-ratio combination CagriSema. The combination was compared with placebo, cagrilintide alone, or semaglutide alone in overweight or obese individuals, and the reported effects on glycaemic control and bodyweight were described as complementary.
Cagrilintide is a calcitonin (CTR)/amylin receptor (AMYR) agonist, meaning it activates these receptors. In the fixed-ratio combination CagriSema, it is paired with the long-acting GLP-1R agonist semaglutide. A review describes cagrilintide as differing from other amylin-based agents in its pharmacokinetic properties and receptor selectivity, ranging from more selective amylin receptor agonists to dual amylin/calcitonin receptor agonists. The same review notes that calcitonin receptor engagement, exposure kinetics and downstream neural circuit recruitment may influence whether reduced food intake reflects physiological satiation or aversive signaling.
Cagrilintide is one of the long-acting amylin-based therapies that a human review describes as having demonstrated clinically meaningful weight loss with generally favorable tolerability profiles. Cagrilintide mimics amylin, a hormone that is co-secreted with insulin from pancreatic β-cells. The review describes amylin's effects as slowing gastric emptying, suppressing glucagon secretion, and promoting satiation through actions in the central nervous system.
In human clinical trials of cagrilintide combined with semaglutide (CagriSema), the safety profile was consistent with the GLP-1 receptor agonist class and with previous safety data for cagrilintide. Most adverse events were mild or moderate and gastrointestinal related, and the adverse events with CagriSema were primarily gastrointestinal and injection-site reactions. No increase in serious adverse events was seen with CagriSema in these human trials. These findings describe the combination of cagrilintide and semaglutide, not cagrilintide given alone.
In a human review, cagrilintide is described as one of the long-acting amylin-based therapies that have shown clinically meaningful weight loss with generally favorable tolerability. In the phase 3a REDEFINE 1 clinical trial, adults without diabetes who had obesity were given cagrilintide 2.4 mg once weekly along with lifestyle intervention. A separate human review lists semaglutide-cagrilintide, a combined form with semaglutide, among the pharmacologic treatments for weight management in overweight or obesity that it included in its study selection.
Cagrilintide is described as a calcitonin (CTR)/amylin receptor (AMYR) agonist. It is combined with the long-acting GLP-1R agonist semaglutide in the fixed-ratio combination CagriSema, where semaglutide is the GLP-1 receptor agonist. A review describes cagrilintide as a long-acting amylin analogue rather than a GLP-1 receptor agonist.
Yes, cagrilintide has been studied on its own in humans, both in a review of study results and in a phase 3a clinical trial. A review reported that cagrilintide monotherapy produced significant reductions in body weight (MD: -6.08%; MD: -5.89 kg) and blood pressure in humans, without meaningful HbA1c improvement. In a meta-analysis of adults with overweight or obesity and type 2 diabetes, CagriSema produced significantly greater percentage body weight reduction than cagrilintide monotherapy (MD -8.15%). In the phase 3a REDEFINE 1 trial, adults without diabetes with obesity were randomised to cagrilintide 2.4 mg once weekly plus lifestyle intervention, alongside CagriSema, semaglutide and placebo arms.
CagriSema is a fixed-dose combination of the amylin receptor agonist cagrilintide and the glucagon-like peptide-1 receptor agonist semaglutide, administered subcutaneously once weekly. Cagrilintide is a calcitonin (CTR)/amylin receptor (AMYR) agonist, and semaglutide is a long-acting GLP-1 receptor agonist; together they form the fixed-ratio combination CagriSema. The combination was described as showing greater efficacy for weight loss compared to GLP-1R and CTR/AMYR mono-agonists alone. CagriSema is delivered in the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of the fixed-dose combination of cagrilintide and semaglutide.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.